MY201928A - Il-5 antibody, antigen binding fragment thereof, and medical application therefor - Google Patents

Il-5 antibody, antigen binding fragment thereof, and medical application therefor

Info

Publication number
MY201928A
MY201928A MYPI2020001584A MYPI2020001584A MY201928A MY 201928 A MY201928 A MY 201928A MY PI2020001584 A MYPI2020001584 A MY PI2020001584A MY PI2020001584 A MYPI2020001584 A MY PI2020001584A MY 201928 A MY201928 A MY 201928A
Authority
MY
Malaysia
Prior art keywords
antibody
antigen binding
binding fragment
medical application
application therefor
Prior art date
Application number
MYPI2020001584A
Inventor
Qiyue Hu
Weikang Tao
Hua Ying
Hu Ge
Yifang Wang
Jinping Shi
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd, Jiangsu Hengrui Medicine Co filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MY201928A publication Critical patent/MY201928A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are an IL-5 antibody, an antigen binding fragment thereof, and a medical application therefor. The present invention comprises a mouse-derived antibody containing an IL-5 antibody CDR region, a chimeric antibody, a humanized antibody, and a pharmaceutical composition comprising said IL-5 antibody and said antigen binding fragment thereof, as well as the use of the pharmaceutical composition as a drug. (FIG. 3)
MYPI2020001584A 2017-09-29 2018-09-28 Il-5 antibody, antigen binding fragment thereof, and medical application therefor MY201928A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710906068 2017-09-29
PCT/CN2018/108240 WO2019062831A1 (en) 2017-09-29 2018-09-28 Il-5 antibody, antigen binding fragment thereof, and medical application therefor

Publications (1)

Publication Number Publication Date
MY201928A true MY201928A (en) 2024-03-24

Family

ID=65900695

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001584A MY201928A (en) 2017-09-29 2018-09-28 Il-5 antibody, antigen binding fragment thereof, and medical application therefor

Country Status (15)

Country Link
US (3) US11365247B2 (en)
EP (1) EP3689906B1 (en)
JP (1) JP7307720B2 (en)
KR (1) KR102709785B1 (en)
CN (1) CN111065651B (en)
AU (1) AU2018340557B2 (en)
BR (1) BR112020005766A2 (en)
CA (1) CA3076941A1 (en)
ES (1) ES3046715T3 (en)
MX (1) MX2020003034A (en)
MY (1) MY201928A (en)
PL (1) PL3689906T3 (en)
TW (1) TWI801425B (en)
WO (1) WO2019062831A1 (en)
ZA (1) ZA202001807B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210145187A (en) * 2019-03-29 2021-12-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Pharmaceutical compositions containing antibodies to IL-5 and uses thereof
CN117903303A (en) * 2020-08-20 2024-04-19 南京融捷康生物科技有限公司 IL-5 binding molecules and uses thereof
WO2025038442A1 (en) * 2023-08-11 2025-02-20 Invetx, Inc. Anti-il-5 antibodies and uses thereof
CN121362251A (en) * 2024-07-19 2026-01-20 普米斯生物技术(珠海)有限公司 Anti-IL-5 antibodies, pharmaceutical compositions and uses thereof
CN120884696A (en) * 2024-08-23 2025-11-04 深圳瑞思普利生物制药股份有限公司 Application of anti-IL-5 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
PL176393B1 (en) 1992-02-06 1999-05-31 Schering Corp Monoclonal antibody or a fragment thereof which becomes bonded to human interleukin-5, hybridoma educing such antibody, polypeptide isolated fron dna, recombined vector of host cell, humanised monoclonal antibody as well as method of obtaining such polypeptide, method of obtaining humanised antibody and pharmaceutic composition
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
KR100509993B1 (en) * 1994-12-23 2006-02-28 스미스클라인비이참피이엘시이 Recombinant IL-5 Antagonists Useful in the Treatment of IL-5 Mediated Diseases
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2277336T3 (en) 1994-12-23 2007-07-01 Smithkline Beecham Corporation ANTIGONISTS OF IL-5 RECOMBINANTS USEFUL IN THE TREATMENT OF ILLNESSES MEDIATED BY IL-5.
CN1326879C (en) 2002-03-29 2007-07-18 先灵公司 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US8192736B2 (en) 2004-10-28 2012-06-05 Kyowa Hakko Kirin Co., Ltd Remedy for endometriosis
EP2641919A3 (en) * 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US20100248971A1 (en) 2007-12-03 2010-09-30 Takashi Inagaki Process for antibody production
JP6147670B2 (en) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Modified antibodies with improved half-life
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
JP7325166B2 (en) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド Bispecific antibody
KR102495432B1 (en) 2014-09-08 2023-02-03 세파론 엘엘씨 Use of reslizumab to treat moderate to severe eosinophilic asthma
MA42692A (en) 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd BIOPHARMACEUTICAL COMPOSITIONS

Also Published As

Publication number Publication date
JP7307720B2 (en) 2023-07-12
EP3689906A4 (en) 2021-04-07
CN111065651A (en) 2020-04-24
RU2020112984A3 (en) 2021-11-25
MX2020003034A (en) 2020-07-22
US20220356239A1 (en) 2022-11-10
US20250333494A1 (en) 2025-10-30
RU2020112984A (en) 2021-10-29
US20200262909A1 (en) 2020-08-20
KR102709785B1 (en) 2024-09-24
AU2018340557A1 (en) 2020-04-09
ES3046715T3 (en) 2025-12-02
CA3076941A1 (en) 2019-04-04
JP2021502801A (en) 2021-02-04
WO2019062831A1 (en) 2019-04-04
US12258394B2 (en) 2025-03-25
TW201915022A (en) 2019-04-16
PL3689906T3 (en) 2025-11-24
CN111065651B (en) 2023-07-14
EP3689906B1 (en) 2025-09-10
EP3689906C0 (en) 2025-09-10
US11365247B2 (en) 2022-06-21
AU2018340557B2 (en) 2025-02-27
TWI801425B (en) 2023-05-11
BR112020005766A2 (en) 2020-10-13
KR20200059239A (en) 2020-05-28
EP3689906A1 (en) 2020-08-05
ZA202001807B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
MX2021005396A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof.
MX2018008592A (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof.
MY208022A (en) Anti-claudin 18.2 antibody and application thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
CY1122245T1 (en) PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MX2025001906A (en) Anti-ror antibody constructs
MY201928A (en) Il-5 antibody, antigen binding fragment thereof, and medical application therefor
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MY208638A (en) Anti-steap1 antigen-binding protein
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
MX2017012965A (en) Anti-c-met antibody and anti-c-met antibody-cytotoxic drug conjugate and pharmaceutical use thereof.
MX2020002750A (en) Il-6r antibody and antigen binding fragment thereof and medical use.
MX2022007959A (en) Novel anti-fgfr2b antibodies.
JOP20190187A1 (en) Anti-ccr7 antibody drug conjugates
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2022007961A (en) Novel anti-fgfr2b antibodies.
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
MX2023004314A (en) Therapeutic anti-cd40 ligand antibodies.
MX2021003168A (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use.
MX2019014375A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof.
MX2020011027A (en) CONSTRUCTS OF TRIVALENT BISECIFIC ANTIBODIES.
MX2019015914A (en) Chimeric antibodies for treatment of amyloid deposition diseases.
MX2019011624A (en) Methods and compositions for reduction of immunogenicity.